Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 13;10(11):1922.
doi: 10.3390/vaccines10111922.

Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina

Diane Uschner  1 , Matthew Bott  1 , William H Lagarde  2 , Joseph Keating  3 , Hazel Tapp  4 , Andrea A Berry  5 , Austin L Seals  6 , Iqra Munawar  7 , John Schieffelin  8 , Joshua Yukich  3 , Michele Santacatterina  1 , Mihili Gunaratne  1 , Lida M Fette  1 , Brian Burke  1 , Greg Strylewicz  1 , Sharon L Edelstein  1 , Amina Ahmed  9 , Kristen Miller  10 , John W Sanders  7 , David Herrington  6 , William S Weintraub  10 , Michael S Runyon  11 , On Behalf Of The Covid-Community Research Partnership
Affiliations

Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina

Diane Uschner et al. Vaccines (Basel). .

Abstract

We characterize the overall incidence and risk factors for breakthrough infection among fully vaccinated participants in the North Carolina COVID-19 Community Research Partnership cohort. Among 15,808 eligible participants, 638 reported a positive SARS-CoV-2 test after vaccination. Factors associated with a lower risk of breakthrough in the time-to-event analysis included older age, prior SARS-CovV-2 infection, higher rates of face mask use, and receipt of a booster vaccination. Higher rates of breakthrough were reported by participants vaccinated with BNT162b2 or Ad26.COV2.S compared to mRNA-1273, in suburban or rural counties compared to urban counties, and during circulation of the Delta and Omicron variants.

Keywords: Ad26.COV2.S; BNT162b2; Delta; Omicron; SARS-CoV-2 vaccination; age; booster vaccination; cumulative incidence; mRNA-1273; rural county.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Cumulative incidence curves of breakthrough infection among participants who reported full vaccination (1 minus the unadjusted Kaplan–Meier risk). Below each graph is the number at risk at each time point for the first self-reported symptomatic positive SARS-CoV-2 test, starting from full vaccination: (A) Overall; (B) By vaccine product; (C) By county classification; (D) By age stratum.
See this image and copyright information in PMC

References

    1. Sadoff J., Gray G., Vandebosch A., Cárdenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Fennema H., Spiessens B., et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19. N. Engl. J. Med. 2021;384:2187–2201. doi: 10.1056/NEJMoa2101544. - DOI - PMC - PubMed
    1. Thompson M.G., Burgess J.L., Naleway A.L., Tyner H., Yoon S.K., Meece J., Olsho L.E.W., Caban-Martinez A.J., Fowlkes A.L., Lutrick K., et al. Prevention and Attenuation of COVID-19 with the BNT162b2 and MRNA-1273 Vaccines. N. Engl. J. Med. 2021;385:320–329. doi: 10.1056/NEJMoa2107058. - DOI - PMC - PubMed
    1. Santacatterina M., Sanders J.W., Weintraub W.S. North Carolina COVID-19 Community Research Partnership Prevention of Covid-19 with the BNT162b2 and MRNA-1273 Vaccines. N. Engl. J. Med. 2021;385:1817–1818. doi: 10.1056/NEJMc2113575. - DOI - PubMed
    1. NC Rural Center. [(accessed on 30 September 2022)]. Available online: https://www.ncruralcenter.org/about-us/
    1. CDC. COVID-19 Vaccine Breakthrough Case Investigations Team COVID-19 Vaccine Breakthrough Infections Reported to CDC—United States, January 1–April 30, 2021. MMWR Morb. Mortal Wkly. Rep. 2021;70:792–793. doi: 10.15585/mmwr.mm7021e3. - DOI - PMC - PubMed

LinkOut - more resources